

#AAD2019

Highlights
AEDV

IN 77TH AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

Scientific Initiative of:



Sponsored by:



#AAD2019

Highlights
AEDV

IN 77TH AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

Cosmetics and lasers
Dr. Guillermo Villalón Gacía

Scientific Initiative of:




Sponsored by:



FILLERS

- Great ethnic variability throughout the world. The art to adapt our techniques.
- HYPER DILUTED FILLER TECHNIQUES. Dilutions with saline or anesthetics. Are coming more common. How much do they last? These way of infiltration are also being applied to thighs, buttocks and arms, specially in Brazil, with polylactic acid and hydroxiapatite.
- Importance of MALAR ENHANCEMENT on global face rejuvenation.
- ECO DOPPLER in fillers. Vascular marking of the face to avoid oclusive phenomena in blood vessels, among other aplications: laser guided elimination of fillers by over heating or locating them to make surgical extrusion.
- Problems: time consuming, patient confort, expensive high quality ecographs, time learning. Does it worth?
- First case of blindness published in 1906 with paraffin.

- TOPICAL CLASCOTERONE 1% CREAM: first topical Androgen Receptor (AR) inhibitor with anti-inflammatory properties. Targets AR receptor in sebocytes and hair papilla by INHIBITION of DHT STIMULATION SIGNALING which includes sebum (lipid production) and cytokine expresión (IL-1B, IL-6, IL8), NF Kappa B activation.
- >9 years of age.
- Safety similar to vehicle.
- Great skin tolerability.
- Abscense of systemic signal effects.
- Improvement in acne lesion count and severity.



CLASCOTERONE TOPICAL SOLUTION in ANDROGENIC ALOPECIA

#AAD2019


Highlights
AEDV

IN 77TH AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

- Studies in phase I and phase II.
- No systemic adverse effects (no interference with blood hormone levels).
- Excellent local tolerability.
- Notable hair growth signal comparable to minoxidil 5%.
- Results from dose ranging study currently underway are expected in 2019.



TOPICAL MINOCYCLINE 4% in ACNE and 1,5% in ROSACEA

Minocycline Foam (FMX101) 4% in Acne Vulgaris

TOPICAL MINOCYCLINE 4% FOAM
BASELINE
WEEK 12

TOPICAL MINOCYCLINE 4% FOAM
BASELINE
WEEK 6
WEEK 9
WEEK 12

Data on File. Foamix Pharmaceuticals, Bridgewater, New Jersey. Study FX2014-03 CSR.

Phase 3 Rosacea Results

Baseline Week 12 IGA=3 IGA=0

Baseline Week 12 IGA=3 IGA=2

ORAL SARECYCLINE

Highlights
AEDV

IN 77TH AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

- In clinical trial.
- Only oral antibiotic acne specific.
- Quick action (3 weeks)
- Children >9 years old.
- High potent activity against *P. acnes* and against gram+ pathogens (*S. aureus*)
- Less impact against enteric gram negative bacteria including commensals of gut flora.
- May lead to less resistance due to its narrow antibacterial profile.

